Trial · NCT07882719
Quadriceps Muscle Activation and Oxygenation Responses During Usual Care Compared to Individualized Interval and Constant Work Rate Bed-cycling. An Experimental Study.
NCT07882719, Not applicable, Not yet recruiting, KU Leuven
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Quadriceps Muscle Activation and Oxygenation Responses During Usual Care Compared to Individualized Interval and Constant Work Rate Bed-cycling. An Experimental Study. Trials, record NCT07882719. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882719
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Quadriceps Muscle Activation and Oxygenation Responses During Usual Care Compared to Individualized Interval and Constant Work Rate Bed-cycling. An Experimental Study.
- NCT number
- NCT07882719
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 29 participants, estimated
- Lead sponsor
- KU Leuven
- Conditions
- Critical Illness
- Interventions
- usual care constant work rate bedcycling, Individualized constant work rate bedcycling, Individualized interval bedcycling
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Average Quadriceps Muscle Activation During Bed-Cycling | During each bed-cycling session (Days 1-3; within a maximum of 5 days). | Average quadriceps muscle activation will be assessed using surface electromyography (sEMG) during the cycling protocols (u-CWR, i-CWR and i-IT). Activation will be expressed as normalized root mean square (RMS) amplitude relative to maximal voluntary contraction (%max), averaged across four quadriceps regions: vastus lateralis, vastus medialis, upper rectus femoris, and lower rectus femoris. |
| Secondary | Quadriceps muscle fatigue (Median Frequency) | During the incremental loading test and each cycling session (Days 0-3; within 5 days). | Muscle fatigue will be assessed by changes in the median frequency (Hz) of the surface electromyography signal over the four quadriceps regions during the incremental loading test and the three cycling protocols. A reduction in median frequency is considered indicative of muscle fatigue. |
| Secondary | Quadriceps muscle fatigue (Frequency ratio) | During the incremental loading test and each cycling session (Days 0-3; within 5 days). | Muscle fatigue will be assessed using changes in the high-frequency to low-frequency ratio of the sEMG signal across the four quadriceps regions during exercise. |
| Secondary | Spatial heterogeneity of quadriceps muscle activation | During the incremental loading test and each cycling session (Days 0-3; within 5 days). | Spatial heterogeneity of quadriceps muscle activation will be quantified as the relative dispersion of normalized sEMG amplitude across four quadriceps regions. Relative dispersion will be calculated as the standard deviation divided by the mean activation across the four regions. |
| Secondary | Quadriceps muscle oxygenation | At rest, during and immediately after the incremental loading test and each cycling session (Days 0-3; within 5 days). | Local quadriceps muscle tissue oxygen saturation (StiO2, %) will be continuously assessed using near-infrared spectroscopy (NIRS) at four muscle regions: vastus lateralis, vastus medialis, upper rectus femoris, and lower rectus femoris. Resting values and oxygenation responses during exercise will be assessed across the cycling protocols. |
| Secondary | Quadriceps muscle hemoglobine and Myoglobine Responses (oxygenated) | At rest, during and immediately after the incremental loading test and each cycling session (Days 0-3; within 5 days). | Near-infrared spectroscopy (NIRS) will be used to assess oxygenated hemoglobin/myoglobin signals in four quadriceps regions during exercise. |
| Secondary | Quadriceps muscle hemoglobine and Myoglobine Responses (deoxygenated) | At rest, during and immediately after the incremental loading test and each cycling session (Days 0-3; within 5 days) | Near-infrared spectroscopy (NIRS) will be used to assess deoxygenated hemoglobin/myoglobin signals in four quadriceps regions during exercise. |
| Secondary | Quadriceps muscle hemoglobine and Myoglobine Responses (total) | At rest, during and immediately after the incremental loading test and each cycling session (Days 0-3; within 5 days). | Near-infrared spectroscopy (NIRS) will be used to assess total hemoglobin/myoglobin signals in four quadriceps regions during exercise. |
| Secondary | Spatial Heterogeneity of Quadriceps Muscle Oxygenation | At rest and during the incremental loading test and each cycling session (Days 0-3; within 5 days). | Spatial heterogeneity of muscle oxygenation will be quantified using the relative dispersion of NIRS-derived muscle tissue oxygen saturation (StiO2) across four quadriceps regions. |
| Secondary | Changes in haert rate during Bed-Cycling | Before, during and immediately after the incremental loading test and each cycling session (Days 0-3; within 5 days). | Hemodynamic responses will be assessed using changes in heart rate (beats/min), measured before, during and after exercise. |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882719
GET https://conductscience.org/api/trials/v1/NCT07882719/registered?page=2